Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial

Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial

Background The failure of cholesteryl ester transfer protein inhibitor torcetrapib was associated with an off‐target increase in plasma aldosterone. We sought to evaluate the impact of evacetrapib on plasma aldosterone level and determine the association between plasma aldosterone level and major ad...

Full description

Bibliographic Details
Main Authors: Anirudh Kumar, Divyang R. Patel, Danielle M. Brennan, Kathy E. Wolski, A. Michael Lincoff, Giacomo Ruotolo, Ellen McErlean, Govinda Weerakkody, Jeffrey S. Riesmeyer, Stephen J. Nicholls, Steven E. Nissen, Venu Menon
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
aldosterone
cholesteryl transfer protein inhibitors
major adverse cardiovascular events
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.119.013790

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.119.013790

Similar Items